Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research
FibroGen anemia drug latest to draw on insights
Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting
You may also be interested in...
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.